Susanne Heynen-Genel's Research Focus
Dr. Heynen-Genel has a multidisciplinary research background, including instrumentation, cell biology, computer programming / software, systems engineering, and multi-variate data analysis. She has been at the forefront of development of the image-based high content screening technology, and has been conducting applied science in phenotypic assay development and screening for over two decades. Her graduate and post-graduate research focused on development and validation of an automated microscopy system followed by its application for cytopathology. This included image analysis, pattern recognition and data mining to take full advantage of the multivariate nature of image-based high-content data. With the maturation of the image-based high-throughput screening technology, she shifted her focus to the application of this exciting new platform to drug discovery – specifically focusing on target identification / validation and phenotypic screening campaigns. In this field, Susanne has collaborated on countless research projects to conceive, design and execute image-based assays applied in small to medium-scale functional genomics and small molecule screens, done with both SBP-based PIs as well as PIs from other academic institutions in the US and abroad. These projects have been instrumental in identifying or validating new targets for characterization and improved understanding of various diseases and for drug discovery. Susanne’s primary research interests and one of her motivations for joining SBP was to take on the challenge of creating an image-based HCS infrastructure, which would push image-based high content screening to applications in large-scale campaigns. The immense success of this endeavor is documented by SBP having been selected as the screening center of choice for image-based HCS projects of the NIH Molecular Libraries Program (MLP). Her successful implementation and constant streamlining of SBP’s high content imaging platform has led to the institute, and specifically the Prebys Center, to be known as one of the few top academic institutes routinely executing image-based screening campaigns of up to 600,000 small molecule compounds in 384- and 1536-well formats, thus fostering collaboration requests for image-based screening projects from across the country. More recently, Susanne has focused on enabling large-scale HCS campaigns using endogenous proteins instead of reporter-based overexpression systems and using more and more biologically relevant systems to better represent the disease phenotypes. The recent reemergence of phenotypic screening as an important approach for discovery of novel classes of drugs combined with new developments in biological models and screening technologies have increasingly brought biological relevance to phenotypic high-throughput screening. Balancing the complexity of the assay systems with screening throughput and chemical compound diversity is a challenge that needs to be specifically tailored for each new assay target and drug discovery screening project. The most recent research focus is on taking full advantage of the highly multiplexed and multi-variate nature of the imaging assay systems, especially when applied as functional secondary or profiling assays.
Susanne Heynen-Genel's Bio
Dr. Susanne Heynen-Genel has over 20 years of experience in image-based screening systems, including automated microscopy instrumentation, image analysis, algorithm development, and HCS assay design. She has been directing development and execution of image-based high-content assays for high-throughput screening (primary screens of large chemical and RNAi libraries) and small scale screening (secondary assays, focused libraries assays for validation of basic research findings) for ten years at the Conrad Prebys Center for Chemical Genomics.
Prior to joining SBP, Susanne was a staff systems scientist at Beckman Coulter, where her responsibilities included system design and integration of high-content screening systems and applications. Previous to that she was an applications scientist for high-throughput microscopy systems at Q3DM until its acquisition by Beckman Coulter. She spent a year as postdoctoral researcher at the University of California in San Diego where she also received her Ph.D. in Bioengineering in 2002. Her graduate student research focused on optimizing fluorometric performance of high-throughput microscopy systems to yield more accurate quantification. This work was incorporated in an image-based HCS platform commercialized first by Q3DM Inc. and then by Beckman Coulter. The accompanying image and single cell data analysis and classification work, initially aimed at detection of cancer cells for cytodiagnostics and presented at conferences, was on the forefront of high-throughput imaging analysis at the time and similar analyses algorithms have more recently been incorporated in commercial HCS image analysis software packages.
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.
Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME
Mol Pharmacol 2010 Oct ;78(4):560-8
Phenothiazine neuroleptics signal to the human insulin promoter as revealed by a novel high-throughput screen.
Kiselyuk A, Farber-Katz S, Cohen T, Lee SH, Geron I, Azimi B, Heynen-Genel S, Singer O, Price J, Mercola M, Itkin-Ansari P, Levine F
J Biomol Screen 2010 Jul ;15(6):663-70
Kim J, Lee JE, Heynen-Genel S, Suyama E, Ono K, Lee K, Ideker T, Aza-Blanc P, Gleeson JG
Nature 2010 Apr 15 ;464(7291):1048-51
Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB
Mol Biol Cell 2016 Sep 1 ;27(17):2757-70
Genome-wide screen identifies novel machineries required for both ciliogenesis and cell cycle arrest upon serum starvation.
Kim JH, Ki SM, Joung JG, Scott E, Heynen-Genel S, Aza-Blanc P, Kwon CH, Kim J, Gleeson JG, Lee JE
Biochim Biophys Acta 2016 Jun ;1863(6 Pt A):1307-18
Cardiac Glycosides Activate the Tumor Suppressor and Viral Restriction Factor Promyelocytic Leukemia Protein (PML).
Milutinovic S, Heynen-Genel S, Chao E, Dewing A, Solano R, Milan L, Barron N, He M, Diaz PW, Matsuzawa S, Reed JC, Hassig CA
PLoS One 2016 ;11(3):e0152692
Roosing S, Hofree M, Kim S, Scott E, Copeland B, Romani M, Silhavy JL, Rosti RO, Schroth J, Mazza T, Miccinilli E, Zaki MS, Swoboda KJ, Milisa-Drautz J, Dobyns WB, Mikati MA, İncecik F, Azam M, Borgatti R, Romaniello R, Boustany RM, Clericuzio CL, D'Arrigo S, Strømme P, Boltshauser E, Stanzial F, Mirabelli-Badenier M, Moroni I, Bertini E, Emma F, Steinlin M, Hildebrandt F, Johnson CA, Freilinger M, Vaux KK, Gabriel SB, Aza-Blanc P, Heynen-Genel S, Ideker T, Dynlacht BD, Lee JE, Valente EM, Kim J, Gleeson JG
Elife 2015 May 30 ;4:e06602
Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.
Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, Gosalia P, Gray W, Mehta A, Sugarman E, Hood B, Suyama E, Nguyen K, Heynen-Genel S, Vasile S, Salaniwal S, Stonich D, Su Y, Mangravita-Novo A, Vicchiarelli M, Roth GP, Smith LH, Chung TD, Hanson GR, Thomas JB, Caron MG, Barak LS, Pinkerton AB
ACS Med Chem Lett 2013 Jul 20 ;4(9):846-851
Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.
Varsano T, Lau E, Feng Y, Garrido M, Milan L, Heynen-Genel S, Hassig CA, Ronai ZA
Clin Cancer Res 2013 May 15 ;19(10):2710-22